Sirolimus improves the two-year outcome of renal allografts in African-American patients

Transplant International

Volumn 14, Issue 3, 2001, Pages 135-142

  Podder, Hemangshu ^a   Podbielski, Jeanette ^a   Hussein, Iman ^a   Katz, Stephen ^a   Van Buren, Charles ^a   Kahan, B D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

African American; Immunosuppression; Pharmacokinetics; Renal transplant; Sirolimus

Indexed keywords

CYCLOSPORIN A; PREDNISONE; RAPAMYCIN;

ACUTE DISEASE; ADULT; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; EVALUATION; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDNISONE; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034919854     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001470100315     Document Type: Article

References (45)

1. Renal transplantation
2. Racial differences in the survival of cadaveric renal allografts: Overriding effects of HLA matching and socioeconomic factors
3. The UNOS scientific renal transplant registry
4. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients
5. Pretransplant test-dose pharmacokinetic profiles: Cyclosporine microemulsion versus corn oil-based soft gel capsule formulation
6. Impact of race on renal transplant outcome
7. Patient noncompliance: A major cause of late graft failure in cyclosporine-treated renal transplants
8. Important risk factors of allograft survival in cadaveric renal transplantation: A study of 426 patients
9. Impact of race on the outcome of renal transplantation under cyclosporine-prednisone
10. Cyclosporine bioavailability: Dosing implications and impact on clinical outcomes in select transplantation subpopulations
11. Sirolimus: A new agent for clinical renal transplantation
12. The role of rapamycin in chronic rejection prophylaxis: A theoretical consideration
13. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay
14. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation
15. The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination
16. Reduced inter- and intra-subject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals
17. Challenges in cyclosporine therapy: The role of therapeutic drug monitoring by area under the curve monitoring
18. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
19. The effect of race on access and outcome in transplantation
20. The adverse impact of cyclosporine on serum lipids in renal transplant recipients
21. Conversion from liquid to solid sirolimus formulations in stable renal allograft transplant recipients
22. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation
23. Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients
24. Stronger immune responsiveness of blacks vs whites may account for renal allograft survival differences
25. Kidney transplants in black recipients. HLA matching and other factors affecting long-term graft survival
26. Improving renal transplant outcomes in African-Americans with OKT3 induction therapy
27. Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and area-under-the-curve monitoring of cyclosporine in renal transplantation
28. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability
29. The adverse impact of high cyclosporine: Clearance rates on the incidences of acute rejection and graft loss
30. Will transplant immunogenetics lead to better graft survival in blacks? Racial variability in the accuray of tissue typing for organ donation: The fourth American workshop
31. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection
32. Immunosuppressive therapy in high-risk transplant patients
33. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine
34. Post-transplant diabetes mellitus in African-Americans after renal transplantation under FK506 immunosuppression
35. Influence of race on kidney transplant survival
36. Kidney graft survival rates in black cyclosporine-treated recipients
37. Racial differences in the incidence of treatment for end-stage renal disease
38. Effect of HLA mismatch in African-Americans
39. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
40. Post-transplant diabetes mellitus and methylprednisolone pharmacokinetics in African-American and Caucasian renal transplant recipients
41. Exchanging donor kidneys
42. Outcome of renal transplantation in blacks
43. In vitro response to immunosuppressive agents in blacks
44. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration